Media Center Investor Relations Overview Investor News Press Releases Company Statements Media Kit Events Stock Information Stock Quote & Chart Analyst Coverage Ownership Profile Financials SEC Filings Annual Reports Governance Governance Documents Committee Composition Investor Resources Investor FAQs Settlement Information Contact Us Investor Email Alerts Investor contact760-603-2331Email Media contact760-603-4679Email Events Upcoming events More events are coming soon. Past events Mar 17, 2026 11:00 AM EDT Stifel 2026 Virtual CNS Forum Listen to webcast Mar 11, 2026 1:30 PM EDT Barclays 28th Annual Global Healthcare Conference Listen to webcast Mar 9, 2026 3:40 PM EDT Leerink Global Healthcare Conference Listen to webcast Mar 2, 2026 10:30 AM EST TD Cowen 46th Annual Health Care Conference Listen to webcast Mar 1, 2026 2026 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting Supporting Materials Additional Benefit of Switching to Donidalorsen for Patients with Hereditary Angioedema Having Breakthrough Attacks Findings from the OASISplus Study 266.7 KB Patient-Reported Disease Control, Work Productivity, and Activity Impairment in Hereditary Angioedema Insights from OASIS-HAE 405.7 KB Predictors of Disease Control, Attack Rate, and Quality of Life in HAE An Exploratory Analysis 203.8 KB Real-world Adherence and Persistence with Long-term Prophylaxis among Patients with Hereditary Angioedema 285.9 KB Rethinking Severity Assessment in Hereditary Angioedema Insights from Patient Experiences 264.9 KB Safety and Efficacy of Donidalorsen in Adolescent Patients With Hereditary Angioedema 1-Year Results From OASISplus 440.6 KB The Relationship Between Objective Disease Control at Baseline and Change in Subjective Disease Control and Quality of Life in Patients with Hereditary Angioedema Receiving Donidalorsen 444.8 KB Unmet Treatment Need in a Real-World US Population of Patients with Hereditary Angioedema Treated for Over a Year with Long-Term Prophylaxis 279 KB Feb 26, 2026 12:00 PM EST Oppenheimer 36th Annual Healthcare Life Sciences Virtual Conference Listen to webcast Feb 25, 2026 8:30 AM EST Fourth Quarter and Full Year 2025 Financial Results Webcast Listen to webcast Supporting Materials Ionis 4Q25 Earnings Slides 3.7 MB Jan 13, 2026 11:15 AM EST 44th Annual J.P. Morgan Healthcare Conference Supporting Materials JPM Presentation 3.9 MB
Upcoming events More events are coming soon. Past events Mar 17, 2026 11:00 AM EDT Stifel 2026 Virtual CNS Forum Listen to webcast Mar 11, 2026 1:30 PM EDT Barclays 28th Annual Global Healthcare Conference Listen to webcast Mar 9, 2026 3:40 PM EDT Leerink Global Healthcare Conference Listen to webcast Mar 2, 2026 10:30 AM EST TD Cowen 46th Annual Health Care Conference Listen to webcast Mar 1, 2026 2026 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting Supporting Materials Additional Benefit of Switching to Donidalorsen for Patients with Hereditary Angioedema Having Breakthrough Attacks Findings from the OASISplus Study 266.7 KB Patient-Reported Disease Control, Work Productivity, and Activity Impairment in Hereditary Angioedema Insights from OASIS-HAE 405.7 KB Predictors of Disease Control, Attack Rate, and Quality of Life in HAE An Exploratory Analysis 203.8 KB Real-world Adherence and Persistence with Long-term Prophylaxis among Patients with Hereditary Angioedema 285.9 KB Rethinking Severity Assessment in Hereditary Angioedema Insights from Patient Experiences 264.9 KB Safety and Efficacy of Donidalorsen in Adolescent Patients With Hereditary Angioedema 1-Year Results From OASISplus 440.6 KB The Relationship Between Objective Disease Control at Baseline and Change in Subjective Disease Control and Quality of Life in Patients with Hereditary Angioedema Receiving Donidalorsen 444.8 KB Unmet Treatment Need in a Real-World US Population of Patients with Hereditary Angioedema Treated for Over a Year with Long-Term Prophylaxis 279 KB Feb 26, 2026 12:00 PM EST Oppenheimer 36th Annual Healthcare Life Sciences Virtual Conference Listen to webcast Feb 25, 2026 8:30 AM EST Fourth Quarter and Full Year 2025 Financial Results Webcast Listen to webcast Supporting Materials Ionis 4Q25 Earnings Slides 3.7 MB Jan 13, 2026 11:15 AM EST 44th Annual J.P. Morgan Healthcare Conference Supporting Materials JPM Presentation 3.9 MB
Mar 1, 2026 2026 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting Supporting Materials Additional Benefit of Switching to Donidalorsen for Patients with Hereditary Angioedema Having Breakthrough Attacks Findings from the OASISplus Study 266.7 KB Patient-Reported Disease Control, Work Productivity, and Activity Impairment in Hereditary Angioedema Insights from OASIS-HAE 405.7 KB Predictors of Disease Control, Attack Rate, and Quality of Life in HAE An Exploratory Analysis 203.8 KB Real-world Adherence and Persistence with Long-term Prophylaxis among Patients with Hereditary Angioedema 285.9 KB Rethinking Severity Assessment in Hereditary Angioedema Insights from Patient Experiences 264.9 KB Safety and Efficacy of Donidalorsen in Adolescent Patients With Hereditary Angioedema 1-Year Results From OASISplus 440.6 KB The Relationship Between Objective Disease Control at Baseline and Change in Subjective Disease Control and Quality of Life in Patients with Hereditary Angioedema Receiving Donidalorsen 444.8 KB Unmet Treatment Need in a Real-World US Population of Patients with Hereditary Angioedema Treated for Over a Year with Long-Term Prophylaxis 279 KB
Additional Benefit of Switching to Donidalorsen for Patients with Hereditary Angioedema Having Breakthrough Attacks Findings from the OASISplus Study 266.7 KB
Patient-Reported Disease Control, Work Productivity, and Activity Impairment in Hereditary Angioedema Insights from OASIS-HAE 405.7 KB
Predictors of Disease Control, Attack Rate, and Quality of Life in HAE An Exploratory Analysis 203.8 KB
Real-world Adherence and Persistence with Long-term Prophylaxis among Patients with Hereditary Angioedema 285.9 KB
Safety and Efficacy of Donidalorsen in Adolescent Patients With Hereditary Angioedema 1-Year Results From OASISplus 440.6 KB
The Relationship Between Objective Disease Control at Baseline and Change in Subjective Disease Control and Quality of Life in Patients with Hereditary Angioedema Receiving Donidalorsen 444.8 KB
Unmet Treatment Need in a Real-World US Population of Patients with Hereditary Angioedema Treated for Over a Year with Long-Term Prophylaxis 279 KB
Feb 26, 2026 12:00 PM EST Oppenheimer 36th Annual Healthcare Life Sciences Virtual Conference Listen to webcast
Feb 25, 2026 8:30 AM EST Fourth Quarter and Full Year 2025 Financial Results Webcast Listen to webcast Supporting Materials Ionis 4Q25 Earnings Slides 3.7 MB
Jan 13, 2026 11:15 AM EST 44th Annual J.P. Morgan Healthcare Conference Supporting Materials JPM Presentation 3.9 MB
